-
Investigators will review latest data from VERTIS-CV trial of SGLT2 inhibitor ertugliflozin
Detailed findings from the VERTIS-CV trial looking at the safety and efficacy of ertugliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, will be presented Tuesday, June 16, by a panel of trial investigators. Christopher P. Cannon, MD, a member of the VERTIS-CV trial Scientific Advisory Committee, will present cardiovascular and renal outcomes from the trial.
-
TEDDY Study providing insight into the type 1 diabetes disease process in children
A panel of investigators, including Beena Akolkar, PhD, will present recent findings from the ongoing TEDDY Study during the Scientific Sessions. TEDDY is a multi-center study funded by the NIDDK designed to investigate the etiology of type 1 diabetes and identify environmental triggers of the disease.
-
Joint symposium to examine role of time-in-range in pediatric diabetes
Ongoing advances in the accuracy and affordability of continuous glucose monitoring technologies have led to a growing emphasis on time-in-range as a primary metric in pediatric diabetes. A panel of experts, including Daniel J. DeSalvo, MD, will review the growing evidence supporting time-in-range and discuss recommendations for incorporating the metric into clinical practice during the…
-
With very few exceptions, Virtual 80th Scientific Sessions will feature entire program planned before COVID-19
On Friday, April 3, the global COVID-19 (coronavirus) pandemic forced the ADA to restructure its flagship professional event from an in-person meeting to a virtual experience to be held over the same dates, June 12-16, 2020. What won’t change, according to Jose C. Florez, MD, PhD, Chair of the 80th Scientific Sessions Meeting Planning Committee,…
-
Panel to explore treatment options tailored to diabetes comorbidities
During a Friday afternoon symposium at the Scientific Sessions, a panel of experts will discuss the latest recommendations and research findings regarding treatment options for patients with common diabetes comorbidities. Panelists include George Bakris, MD, Silvio E. Inzucchi, MD, and Jesse Dawson, MD, BSc (Hons), FRCP, FESO.